10 August 2026
Coiled Therapeutics plc
("Coiled Therapeutics" or the "Company")
Change of Registered Office
Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF), the clinical-stage precision oncology company developing differentiated small molecule therapies for genetically defined cancers, announces that, with immediate effect, the registered office of the Company has changed to 167-169 Great Portland Street, 5th Floor, London W1W 5PF, United Kingdom.
-Ends-
Enquiries:
|
Coiled Therapeutics plc Sotirios Stergiopoulos (Chairman) Sridhar Vempati (CEO) |
Via Burson Buchanan |
|
SP Angel Corporate Finance LLP (Nominated Adviser & Joint Broker) David Hignell / Adam Cowl / Devik Mehta (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking) |
+44 (0)20 3470 0470 |
|
Shard Capital Partners LLP (Joint Broker) Damon Heath CPS Capital Group Pty Ltd (Joint Broker) Jason Peterson / David Valentino |
+44 (0)20 4530 6926 +61 (0)8 9223 2222 |
|
Burson Buchanan (Public Relations) Henry Harrison Topham / Jamie Hooper / Toto Berger |
+44 (0)20 7466 5000 |
|
Harbor Access (US Investor Relations) Matt Kelly / Jonathan Paterson |
+1 475 477 9404 |
About Coiled Therapeutics plc
Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF) is an AIM-listed, clinical-stage precision oncology company advancing first-in-class small molecule therapies targeting validated cancer dependencies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently being evaluated in a Phase I clinical trial in the U.S. (ClinicalTrials.gov ID: NCT06136884). The Company's clinical development strategy is designed to generate the clinical evidence sought by potential pharmaceutical partners in selected tumour types, including ovarian and prostate cancer, while advancing a broader pipeline that includes a STAT6 siRNA programme for immunology indications.
About AO-252
AO-252 is a first-in-class, orally administered, brain-penetrant small molecule designed to selectively inhibit Transforming Acidic Coiled-Coil containing protein 3 (TACC3). TACC3 has emerged as a validated cancer dependency across multiple aggressive solid tumours and is largely dispensable in normal adult cells, supporting the potential for a broad therapeutic window.
By disrupting TACC3-driven protein interactions, AO-252 induces mitotic and replication stress, impairs DNA damage repair and promotes cancer cell death. Its ability to cross the blood-brain barrier is a key differentiator, supporting its potential to treat both primary brain tumours and brain metastases.
AO-252 is currently being evaluated in an ongoing Phase I open-label dose-escalation study. The Company plans to initiate Phase I/II dose-expansion cohorts in ovarian and prostate cancer in H2 2026.
For more information, please visit: www.coiledplc.com and follow us on LinkedIn.